A 26-color staining panel was developed to profile human antigen-specific T cells in an intracellular cytokine staining (ICS) assay using peptide pools to various antigens of interest. In addition to multiple functional markers, the panel includes differentiation/activation markers and markers to assess γδ, mucosal-associated invariant T, and NK T cells as well as conventional NK cells. Panel optimization was performed using previously cryopreserved PBMC from healthy adults, and then, expression of key functional markers in the panel was cross-validated against a validated ICS assay used in the HIV Vaccine Trials Network (HVTN). The panel is currently being used to evaluate the responses to tuberculosis and malaria vaccine candidates in volunteers from different geographic areas.
DESPITE extensive research and clinical testing, highly effective vaccines against complex pathogens such as HIV, tuberculosis (TB), and malaria have not yet been developed. An impediment to this development is the lack of known immune correlates of protection to the pathogens. Multicolor flow cytometry, and in particular, new technologies allowing up to 28-color flow cytometry, could enable identification of novel immune correlates of risk or protection.
Within our HIV Vaccine Trials Network (HVTN) Laboratory Center, intracellular cytokine staining (ICS) is used to quantify and profile T-cell responses to vaccine candidates. The laboratories adhere to good clinical laboratory practices (GCLP), and thus, our ICS assays are validated for the primary functional markers. A prerequisite of applying this new panel in vaccine studies was to retain the same sensitivity for expression of the functional biomarkers IFN-γ, IL-2, TNF-α, and CD40L as in prior ICS assays widely used within the HVTN (1, 2) .
Because this staining panel was designed to elucidate potential immune correlates in a TB vaccine efficacy clinical trial, markers proposed for the panel were prioritized based on the types of immune responses that could be important for control of TB (in order of priority): 1) lineage and viability: CD3, CD4, CD8, CD14, viability; 2) functional markers: IFN-γ, IL-2, TNF-α, CD40L, IL-17, granzyme A, Th2 cytokines (IL-4/IL-13 combined for one detector); 3) memory markers: CCR7, CD45RA; 4) additional lineage markers: γδ TCR, CD56, CD16; 5) MAIT cells: CD161, CD26, Vα7.2; 6) activation: HLA-DR; 7) chemokine receptor for helper 1 Cape Town HVTN Immunology Laboratory, Cape Town, South Africa T cell classification: CXCR3, CCR6; 8) additional functional markers: IL-22, perforin; and 9) differentiation markers: KLRG-1, PD-1.
Although the BD FACSymphony instrument currently includes capability for 28 markers, designing panels that use all available detectors can be challenging. Because we were initially concerned that there is a limited choice for conjugated reagents for the G710 detector, and the fluorochrome commonly used for this detector (PE-Cy5.5) is spectrally similar to fluorochromes detected in the B710 detector (PerCP-Cy5.5 and BB700), our aim was to develop a panel for 27 markers (or colors). Many panel versions were tested, and one detector (B610 for detection of BB630) was shown to cause many spreading issues into other detectors, as assessed by fluorescence minus one (FMO) testing. The B610 detector was therefore not used, although additional optimization would likely have enabled use of this detector. Thus, the final panel included 26 markers (Tables 1 and 2 ). Among the list of markers above, PD-1 was considered lower priority and was dropped. Figure 1 shows an example of the staining profile for PBMC stimulated with staphylococcal enterotoxin B. Although this panel was initially developed for peptide pool antigens, other types of antigens such as recombinant proteins or whole pathogens have also be tested using this panel. Further developmental strategies and details for the panel may be found in the online material. Fig. 6 ). The labels above each graph indicate the cells included in that graph.
SIMILARITY TO PUBLISHED OMIPS
This panel is unique in the combination of functional and phenotypic markers, but it can be considered an expansion of two of our prior ICS assays, OMIP-014 (1), and OMIP-025 (2) .
